全文获取类型
收费全文 | 16079篇 |
免费 | 1011篇 |
国内免费 | 331篇 |
专业分类
耳鼻咽喉 | 36篇 |
儿科学 | 448篇 |
妇产科学 | 147篇 |
基础医学 | 2453篇 |
口腔科学 | 115篇 |
临床医学 | 812篇 |
内科学 | 2362篇 |
皮肤病学 | 132篇 |
神经病学 | 125篇 |
特种医学 | 107篇 |
外国民族医学 | 1篇 |
外科学 | 387篇 |
综合类 | 1301篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 6930篇 |
眼科学 | 69篇 |
药学 | 1128篇 |
4篇 | |
中国医学 | 68篇 |
肿瘤学 | 793篇 |
出版年
2024年 | 21篇 |
2023年 | 552篇 |
2022年 | 997篇 |
2021年 | 893篇 |
2020年 | 714篇 |
2019年 | 629篇 |
2018年 | 682篇 |
2017年 | 593篇 |
2016年 | 603篇 |
2015年 | 695篇 |
2014年 | 806篇 |
2013年 | 1199篇 |
2012年 | 871篇 |
2011年 | 1002篇 |
2010年 | 827篇 |
2009年 | 797篇 |
2008年 | 503篇 |
2007年 | 664篇 |
2006年 | 570篇 |
2005年 | 507篇 |
2004年 | 474篇 |
2003年 | 426篇 |
2002年 | 343篇 |
2001年 | 310篇 |
2000年 | 262篇 |
1999年 | 249篇 |
1998年 | 167篇 |
1997年 | 166篇 |
1996年 | 116篇 |
1995年 | 88篇 |
1994年 | 77篇 |
1993年 | 77篇 |
1992年 | 55篇 |
1991年 | 54篇 |
1990年 | 54篇 |
1989年 | 62篇 |
1988年 | 50篇 |
1987年 | 36篇 |
1986年 | 37篇 |
1985年 | 63篇 |
1984年 | 35篇 |
1983年 | 20篇 |
1982年 | 20篇 |
1981年 | 16篇 |
1980年 | 10篇 |
1979年 | 7篇 |
1978年 | 8篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1974年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
While two prophylactic HPV vaccines have been proven notably efficacious in clinical trials, the effectiveness of these vaccines at the population level remains to be evaluated. To lay the foundation for understanding the strengths and limitations of different endpoints for future effectiveness research, we present a comprehensive review of HPV-related clinical outcomes, including: (i) HPV type-specific positivity and persistence, (ii) Pap diagnoses (ASC-US, LSIL, and HSIL), (iii) histologic cervical cancer precursor lesions (i.e., CIN1, CIN2, and CIN3), (iv) invasive cervical cancer (ICC), (v) anogenital warts, (vi) recurrent respiratory papillomatosis (RRP), and (vii) other HPV-associated cancers (vulvar, vaginal, anal, penile, and oropharyngeal). While research on the vaccines’ effects on these HPV clinical outcomes in the general population is presently limited, numerous large trials will soon be completed, making a priori discussion of these potential outcomes especially urgent. Furthermore, population level systems to track HPV-associated clinical outcomes may need to be developed for HPV vaccine effectiveness evaluation. 相似文献
12.
目的检测以质粒pIRES为载体构建的带有全序列癌胚抗原(CEA)基因的核苷酸疫苗对机体特异性抗肿瘤免疫反应的激活效果。方法将CEA基因片段连接于真核表达质粒pIRES中,用肌肉注射方法接种核酸疫苗;检测CEA在小鼠肌肉组织中的表达情况及其对小鼠脾细胞CEA特异性细胞免疫反应的激活效果。结果小鼠经肌肉注射质粒后,免疫组化证实该核酸疫苗可在体内有效表达CEA;分子免疫检测显示注射后小鼠特异性淋巴细胞增值反应明显并且伴有自然杀伤细胞NK活性显著增高。结论实验所构建的核酸疫苗pIRESCEA可在体外及小鼠体内高效表达并表现出良好的细胞免疫原性。 相似文献
13.
G. Giammanco V. De Grandi L. Lupo A. Mistretta S. Pignato D. Teuween H. Bogaerts F. E. Andre 《European journal of epidemiology》1988,4(1):121-123
A vaccination trial, performed on 86 3-month-old infants, has shown that the ability of the RIT 4237 live attenuated rotavirus strain to induce seroconversion is dramatically reduced when administered with live poliovirus vaccine. In a subsequent trial performed on 93 infants the attempt to overcome the poliovirus interference by administering two doses of associated vaccines was unsuccessful. No interference by the RIT 4237 strain on live attenuated polioviruses was observed. 相似文献
14.
北京市1989~2002年疫苗相关麻痹型脊髓灰质炎病例的监测 总被引:13,自引:2,他引:11
北京市急性弛缓性麻痹 (AFP)病例监测系统 1989~ 2 0 0 2年共诊断疫苗相关麻痹型脊髓灰质炎 (脊灰 )(VAPP) 2 0例 ,其中首次服苗VAPP 18例 ,接触服苗VAPP 2例。所有病例均 <2岁 ,<6月龄病例占 85 %。男女发病之比为 9∶1。每年VAPP发生率无明显季节性高峰和地区差异。VAPP总发生率为 1 2 0 / 10 0万剂口服脊灰减毒活疫苗 (OPV)投放量或 1 5 9/ 10 0万剂OPV接种量 ,首次服苗VAPP发生率为 13 18/ 10 0万剂首次服苗量 ,接触服苗VAPP发生率为 0 16 / 10 0万剂OPV接种量。监测结果表明 ,北京市VAPP发生的危险性高于中国其它省份和其它许多国家与地区 ;免疫缺陷和 /或肛门周围脓肿可能是VAPP重要的危险因素。在中国当前尚未改变脊灰疫苗免疫策略的情况下 ,为减少和避免VAPP的发生 ,必须加强接种前儿童病史询问和体检 ,严格掌握接种禁忌证 ;同时要加强对VAPP的监测工作。 相似文献
15.
赖型钩体flaB2与VR1012中的CpG基序分析 总被引:3,自引:0,他引:3
目的:对问号赖型钩端螺旋体(赖型钩体)DNA疫苗[包括内鞭毛蛋白基因(flaB2)和质粒DNA表达载体(VR1012)]的CpG基序(CpG motifs)进行分析,为DNA疫苗免疫机制的阐明和提高DNA疫苗的效能奠定基础。方法:以flaB2与VR1012构建重组DNA的免疫原,对flaB2及VR1012全核苷酸序列进行计算机分析(分类、计数和定位)。结果:CpG的“C”的侧翼为两个嘌呤,“G”的侧翼为两个嘧啶,在flaB2中共3个,分别为GACGCT,GACGTC和GACGCC;在VR1012中共11个,分别为GACGTC1个,GACGCT2个,GACGCC1个,GACGTT1个,GGCGTT2个,GGCGCT2个,GGCGCC1个,AACGCT1个,其中特别重要的TGACGTCA4个和TAACGCCA有1个,位于5'端456-463;509-516;592-599;778-785和486-493;4个TGACGTCA和1个TAACGCCA均位于5'端且相对集中。结论:赖型钩体flaB2与VR1012构成的DNA疫苗含有TGACGTCA等CpG,这些基序又称免疫刺激序列,构成了DNA疫苗中的佐剂。 相似文献
16.
变形链球菌表面蛋白和葡糖基转移酶基因疫苗对唾液变形链球菌和牙菌斑的影响 总被引:2,自引:0,他引:2
目的 了解变形链球菌表面蛋白和葡糖基转移酶基因疫苗单独及联合免疫对定菌鼠唾液变链菌和牙面菌斑的影响。方法 2 8d龄 Wistar大鼠 3 6只 ,随机分为 pc DNA3 - pac组、pc DNA3 - gtf B组、pc DNA3 - pac联合pc DNA 3 - gtf B组、变形链球菌灭活全菌组、pc DNA3空载体组和 PBS液组 ,进行三次双侧颌下腺腺周注射免疫 ,建立定菌鼠模型 ,作诱龋实验 3个月。唾液变链菌计数和菌斑计分。结果 唾液变链菌菌落计数和牙面菌斑计分在 pc D-NA3与 PBS组最高 ,其次为单基因疫苗免疫组 ,联合基因疫苗和灭活全菌细胞免疫组最低 ,各组间有显著性差异 ( P<0 .0 5 )。结论 pc DNA3 - gtf B和 pc DNA3 - pac具有明显的免疫抑菌作用 ,联合基因疫苗免疫优于单基因疫苗 相似文献
17.
18.
本文应用脱脂奶粉代替小牛胸腺DNA等大分子物质配制预杂交液和杂交液进行核酸分子杂交,同时用经典的含小牛胸腺DNA等大分子物质的预杂交液和杂交液作为对照。结果表明,用脱脂奶粉可以代替小牛胸腺DNA等大分子物质进行核酸分子杂交,此法经济,配制简便,实际可用。 相似文献
19.
Dengue is a mosquito-borne viral disease caused by four antigenically distinct serotypes of dengue viruses (DENVs). This disease, which is prevalent in over a hundred tropical and sub-tropical countries of the world, represents a significant global public health problem. A tetravalent dengue vaccine capable of protecting against all four DENV serotypes has been elusive so far. Current efforts are focused on producing a tetravalent vaccine by mixing four monovalent vaccine components. In this work, we have utilized a discrete carboxy-terminal region of the major DENV envelope (E) protein, known as domain III (EDIII), which mediates virus entry into target cells and contains multiple serotype-specific neutralizing epitopes, to create a chimeric tetravalent antigen. This antigen derived by in-frame fusion of the EDIII-encoding sequences of the four DENV serotypes was expressed using a replication-defective recombinant human adenovirus type 5 (rAdV5) vaccine vector. This rAdV5 vector induced cell-mediated immune responses and virus-neutralizing antibodies specific to each of the four DENVs in mice. Interestingly, anti-AdV5 antibodies did not suppress the induction of DENV-specific neutralizing antibodies. We observed that anti-AdV5 antibodies in the sera of immunized mice could promote uptake of a rAdV5-derived reporter vector into U937 cells, suggesting that pre-existing immunity to AdV5 may in fact facilitate the uptake of rAdV5 vectored vaccines into antigen presenting cells. This work presents an alternative approach to developing a single component tetravalent vaccine that bypasses the complexities inherent in the currently adopted four-in-one physical mixture approach. 相似文献
20.
Z. Peng Q. Liu Q. Wang E. Rector Y. Ma R. Warrington 《Clinical and experimental allergy》2007,37(7):1040-1048
BACKGROUND: Immunotherapy with anti-IgE antibodies for treatment of allergy is promising but a short half-life and extremely high cost limit its application. OBJECTIVE: We sought to develop IgE vaccines that induce longer-lasting auto-antibodies to neutralize self-IgE as an alternative therapy. METHODS: The vaccine was made by conjugating three synthetic peptides corresponding to human IgE receptor-binding sites to a carrier, hepatitis B surface antigen. To test the immunogenicity of the vaccine, rats were immunized with the vaccine or hepatitis B surface antigen as control. Serum IgG titres to human IgE and the IgE of other species were measured. The inhibition by rat antisera of the binding of human IgE to its receptor was assessed by ELISA, flow cytometry analysis, and passive cutaneous anaphylaxis (PCA), and its ability to recognize receptor-bound IgE was examined. The in vivo effect of the vaccine was evaluated in trichosanthin-sensitized mice and rats. In the preventative study, vaccination started before sensitization commenced, while in the treatment study, vaccination started after sensitization. Sensitized mice and rats receiving injections of the carrier served as controls. Trichosanthin-specific IgE was measured using PCA. RESULTS: Sera from vaccine-immunized rats contained high titre antibodies that reacted with soluble and plate-bound but not with receptor-bound human IgE; they also reacted with mouse, rat, and dog IgE. Furthermore, the sera inhibited the binding of human IgE to its receptor in a dose-dependent manner. In preventative and treatment studies, serum trichosanthin-specific IgE levels were significantly reduced in vaccinated groups compared with controls. CONCLUSION: Antibodies against self-IgE can be induced by IgE peptide-based vaccines, which are effective in preventing the increase of IgE and in down-regulating IgE in sensitized animals. 相似文献